The IL-6 receptor antagonist SANT-7 overcomes bone marrow stromal cell-mediated drug resistance of multiple myeloma cells.

摘要: The bone marrow micro-environment produces a number of different survival factors that are important for the malignant growth and drug resistance multiple myeloma (MM) cells. One main reported to be essential MM cells in some experimental systems is IL-6. Therefore, development testing substances interfere with IL-6 or receptor (IL-6R) function might have therapeutic value treatment MM. We analyzed effect IL-6R antagonist SANT-7 on IL-6--dependent cell lines INA-6 XG-1 as well primary from 7 patients co-cultured stromal (BMSCs). In particular, we were interested whether enhances growth-inhibitory effects dexamethasone (Dex) all-trans-retinoic acid (ATRA). None drugs when tested single substance, including SANT-7, induced major inhibition if human BMSCs. However, Dex ATRA given combination strong was achieved This due cell-cycle arrest induction apoptosis.